Should the FDA be the doctor of last resort?
Vincent T DeVita Jr
This article has no abstract so we have provided the first paragraph of the full text.
In this issue of the journal, Seeber and Braun highlight that, after FDA approval, new drugs are not made available to patients other than in ways approved and dictated by specific trials. Trial design is often flawed by restricted access to investigational drugs in the control arm of these studies. The FDA, by implication, has become the oncologist of last resort, overriding the training and experience of practicing physicians.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.